A virus-like particle that can be obtained by (a) transfection of a human cell with a modified EBV genome, wherein said modified EBV genome, compared to a wild-type EBV genome, at least (aa) it lacks one or more sequences that are required for the packaging of said wild-type EBV genome, it lacks one or more sequences encoding the EBV polypeptides required for said packaging and / or comprises one or more sequences encoding EBV polypeptides whose packing capacity is disabled； (ab) it lacks one or more sequences encoding EBV polypeptides that are required for the transformation of B lymphocytes and / or comprises one or more sequences encoding EBV polypeptides whose B lymphocyte transformation capacity is disabled； and (ac) lacks one or more sequences encoding EBV polypeptides that are required to induce EBV replication and / or comprises one or more sequences encoding EBV polypeptides whose ability to induce EBV replication is disabled； (b) cell culture obtained in step (a) under conditions that allow the expression of said modified EBV genome； (c) induction of the EBV replicative phase； and (d) isolation of said particle for use in a method for eliciting a CD8 + cellular immune response specific for therapeutic or prophylactic EBV and a humoral immune response in a human individual, said method comprising administering said particle to said human individual.Una partícula similar a virus que se puede obtener mediante (a) transfección de una célula humana con un genoma de VEB modificado, en el que dicho genoma de VEB modificado, en comparación con un genoma de VEB de tipo natural, al menos (aa) carece de una o más secuencias que se requieren para el empaquetamiento de dicho genoma de VEB de tipo natural, carece de una o más secuencias que codifican los polipéptidos de VEB requeridos para dicho empaquetamiento y/o comprende una o más secuencias que codifican polipéptidos de VEB cuya capacidad de empaquetamiento está inhabilitada； (ab) carece de una o más secuencias que
